A video podcast by the American Society for Microbiology that highlights the latest in microbiology, life science and biotechnology news. ASM is composed of over 42,000 scientists and health professionals with the mission to advance the microbial sciences as a vehicle for understanding life processes and to apply and communicate this knowledge for the improvement of health and environmental and economic well-being worldwide. For information about ASM and MicrobeWorld, visit us online at www.microbeworld.org. For questions and/or feedback please email firstname.lastname@example.org.
Anna Kavanaugh hosts the weekly radio series, "Mad Science: The Genetic Crossroad." The program aims to raise awareness and provide education about genetically modified organisms (GMO), in the world food supply and the practices of the GM biotech industry. The series is dedicated to all issues surrounding GM foods, its usage and ramifications thereof. Anna is a writer, advocate, and founder of the (AKCF) Anna Kavanaugh Charitable Foundation. Her original novel, "The Cord of Callows," now an upcoming expanded trilogy series, is the inspiration for a GMO documentary film entitled, "The Cord of Callows trilogy: Fact Behind the Fiction. Fear Behind the Fact."
Dr. Jason Franasiak, Attending Physician at the Reproductive Medicine Associates of New Jersey, spoke to CHI to discuss the origins of germ theory and human microbiome research, specifically as it relates to human reproduction. He'll detail some of his research on the uteran microbiome during embryo implantation, future developments for diagnostics, and how other scientists may utilize his research and apply it to their own studies. Dr. Franasiak is one of our speakers for the Advances in Microbiome Diagnostics symposium, taking place August 26, 2016 in Washington, DC as part of the Next Generation Dx Summit. For details, visit www.NextGenerationDx.com/Microbiome-Diagnostics
Written and Produced by Erika Shugart, PhD Narration by Chaseedaw Giles Filmed and Edited by Sam Mandl and Chris Condayan Production Supervisor Katherine Lontok, PhD Additional Video Footage by NASA's Goddard Space Flight Center Photography and Illustrations from http://iStockphoto.com http://wikimedia.org http://epa.gov http://cdc.org/phil Royalty Free Music by "Fearless" by Reaktor Productions "Easy Does It" by Olive Musique "Green Fever" by Flash Fluharty "Where I am From" by Topher Mohr and Alex Elena "Back of the Room Hang" by Jingle Punks Additional Photography "Nitrogen Defeciency in Wheat" by CIMMT on Flickr Creative Commons Attribution-Share Alike 3.0 Unported "Material Girl" Madonna Parody Performed by Chaseedaw Giles Music track courtesy of Karaoke Version and Tency Music http://www.karaoke-version.com http://www.tencymusic.com
By email@example.com (American Society for Microbiology)
Global innovation activity experienced broad gains across industry sectors last year, according to Thompson Reuters newly released 2016 State of Innovation report. We spoke to Anthony Trippe, senior patent analyst for Thomson Reuters about the report, its upbeat outlook, and what it says about the direction of innovation in the biotechnology, pharmaceutical, and medical device sectors.
Jeffrey Borenstein of Draper Laboratory speaks to Cambridge Healthtech Institute on May 9, 2016. Dr. Borenstein will present during the 3D Cellular Models meeting, part of the World Preclinical Congress, June 14-17 in Boston, Massachusetts. Topics include promising methods for recapitulating the in vivo microenvironment in 3D cell culture models, microfluidic technologies for multiplexed and interacting organ models, microsystems-based approaches for organ assist devices and organ models for drug efficacy and safety testing, and Draper Lab’s resources for that research. For more information, please visit http://www.WorldPreclinicalCongress.com/
The Campaign for Sustainable Rx Pricing, a coalition of healthcare stakeholders, thinks that the rising cost of prescription drugs can be addressed through a series of market-based solutions that will strike a balance between preserving innovation and ensuring affordability. Its recently released plan outlines steps to increase transparency, competition, and value. We spoke to John Rother, executive director of the Campaign for Sustainable Rx Pricing, about the organization, its focus on market-based solutions, and what it will take to make them a reality.
The emergence of smartphones at the center of a growing universe of digital health devices is giving rise to new ways to monitor and measure our bodies in real time. MyDx, one of the latest entrants into this area, is working to enable consumers to test the food they eat, the water they drink, and the air they breathe to ensure they’re safe. Its first offering allows cannabis users to analyze samples for THC content, the presence of pesticides, and their potential effects on users. We spoke to Daniel Yazbeck, chairman and CEO of MyDx, about his handheld analyzer, how it works, and how he expects it to both enable and be fueled by changing consumer behavior in the emerging world of the quantified self.
Joerg Holenz of AstraZeneca previews his in-depth course on Modern Lead Generation Strategies and highlights the important issues on this subject. Joerg will be speaking during the Mastering Medicinal Chemistry meeting, June 15-16, in Boston, MA. For more information, please visit http://www.WorldPreclinicalCongress.com/
Dr. Robert D. Bell, Principal Scientist, Integrative Neuroscience at Pfizer spoke to CHI to discuss challenges in in researching the blood-brain barrier for creating effective treatments, as well as future directions and potential research avenues. He also discussed the topics and speakers he’s excited to see at the Blood-Brain Barrier conference this June. Dr. Bell is one of our chairpeople and roundtable moderators at the Blood-Brain Barrier conference, taking place June 15-16, 2016 in Boston, MA as part of the World Preclinical Congress. For details, visit http://www.WorldPreclinicalCongress.com/Blood-Brain-Barrier/
Victoria Mosolgo interviews Dr. Tom Laue of the University of The University of New Hampshire. Dr. Laue will be giving a keynote presentation in the High-Concentration Protein Formulations track at the 8th Annual Bioprocessing Summit taking place August 15-19, 2016 in Boston. To learn more, visit http://www.BioprocessingSummit.com/
Muneesh Tewari of the University of Michigan speaks to Cambridge Healthtech Institute on April 28, 2016. Dr. Tewari will give his keynote presentation during the conference program at The Liquid Biopsy Summit, June 22-24 in San Francisco, California. Topics include circulating extracellular RNAs as a liquid biopsy approach, developing novel biomarker methods that involve serial monitoring at high-time resolution, and researching circulating microRNA biomarkers for cancer and other diseases with a diverse scientific and medical background. For more information, please visit http://www.LiquidBiopsySummit.com/
The Obama Adminstration’s Cancer Moonshot initiative is a boost to cancer researchers, but Bruce Zetter says in order for it be as effective as possible, it must not repeat the same funding priorities of the past and instead should support innovative projects and research against the deadliest cancers. In a recent commentary in Politico, Zetter, a professor of cancer biology at Harvard Medical School and Boston Children’s Hospital, notes that researchers follow the money and that the cancers with which we have made the least progress still seem to get the least amount of funding. We spoke to Zetter about his commentary, the opportunities being created by the Cancer Moonshot, and how he thinks cancer funding needs to change.
Jamie Platt of BRIDGenomics, LLC speaks to Cambridge Healthtech Institute on April 21, 2016. Dr. Platt will give her presentation during the conference program at The Liquid Biopsy Summit, June 22-24 in San Francisco, California. Topics include changes in the landscape of development and commercialization of molecular diagnostics, issues and emerging opportunities for liquid biopsy sample prep, and process/technology refinements necessary for broader, routine application of liquid biopsies. For more information, please visit http://www.LiquidBiopsySummit.com/
For people with type I diabetes, the day-to-day management of the disease can be a full-time job involving the monitoring blood glucose levels and injection of insulin. The medical device giant Medtronic has been working toward the development of what it’s called an artificial pancreas, a steady improvement of pump and sensor technology to free type I diabetes patients and allow them to think less about the management of their disease. We spoke to Fran Kaufman, chief medical officer of Medtronic Diabetes, about the progress the company has made, its newest technology that is moving towards the market, and how close it is to realizing its vision of an artificial pancreas.
By using data from routine testing about the genetic evolution of the HIV /AIDS virus in the Canadian province of British Columbia, researchers have shown they are able to identify emerging outbreaks of the disease in near real-time and intervene to control its spread. The first-of-its-kind system is the focus of a study in an April edition of The Lancet HIV. We spoke to Art Poon, Associate Research Scientist for the British Columbia Centre for Excellence in HIV/AIDS and lead author of the study, about the monitoring system, the impact it has had, and whether such an approach is transferable to other regions and other disease outbreaks.
Dr. Cory Abate-Shen of Columbia University Medical Center speaks to CHI on April 8th , 2016. Dr. Abate-Shen will be presenting during the Preclinical Models in Oncology conference at the 2016 World Preclinical Congress, June 14-17 in Boston, MA. For more information, please visit http://www.WorldPreclinicalCongress.com/Cancer-Models/
As pricing pressure grow on the pharmaceutical industry, a recent article in Invivo argues that drugmakers must look to a variety of new pricing models built around collaborations with payers and providers. Such an approach, the authors argue, would minimize conflicts between stakeholders, close the information gap about the real-world value of new drugs, and allow for a more evidence-based approach to pricing. We spoke to Susan Garfield, a principal in EY's Life Sciences Advisory Services practice and co-author of the Invivo article, about the need for new approaches to pricing, why the existing unit price approach is too one-dimensional, and what’s at stake for the industry if it fails to innovate new models.
The France-based biotech Gensight Biologics is developing gene therapy treatments for rare, mitochondrial, and neurodegenerative diseases of the eye. Its lead therapeutic candidate is in late-stage trials for Leber’s Hereditary optic neurophathy, a sudden condition that afflicts young adults and leaves almost all of them blind. We spoke to Gensight’s CEO Bernard Gilly about the company, the challenges and promises of gene therapy, and why eye disease is a particularly attractive target for this emerging area of treatment.
Nearly $3 billion a year is wasted on cancer drugs because of the way they are packaged, according to a study in BMJ. These expensive drugs that are injected or infused come in fixed size vials and patients often require less drug than what is sold as a single dose. Because of restrictions on the ability to use leftover drug, the result is that it is usually thrown out. Nevertheless, drugmakers have little incentive to do things differently because the waste enhances their profitability. We spoke to Leonard Saltz, an oncologist with Sloan Kettering Memorial Cancer Center and coauthor of the study, about the findings, why Europe doesn’t have the same problem, and what can be done to stop the waste.
The walking dead live, but it's value, not brains, they are eating. So-called zombie funds, life sciences venture capital funds that are fully invested and unable to raise new money, still maintain their board seats. But Outcome Capital’s Managing Directors Oded Ben-Joseph and Arnie Freeman say their divergent interest from their fellow board members often lead to disputes that can end the life of promising technologies and lead to acquisitions that leave much value on the table. We spoke to Ben-Joseph and Freeman about the boardroom dynamics were zombies lurk, the consequence of this board misalignment, and how acquirers may seek to leverage the situation
Daniel Cohen discusses the industrialization of genomic sequencing, his part in founding Millennium and why the conductor has the most difficult job in an orchestra.
By firstname.lastname@example.org (Nature Biotechnology)
Last month, the Senate confirmed Robert Califf, a cardiologist and clinical researcher from Duke University, as commissioner of the U.S. Food and Drug Administration. Though he was overwhelming confirmed, some expressed concerns about his ties to the pharmaceutical industry. Others used the confirmation process to protest the FDA’s handling of opioid painkillers as the problem of addiction to these drugs have become a growing concern. We spoke to Peter Pitts, a former FDA associate commissioner and president of the Center for Medicine in the Public Interest, about Califf, why he’s well suited for the job, and the challenges he will face in his new role.
Bird Rock Bio, a small, San Diego-based biotech, is planning to take aim at some of the biggest biologics on the market with an antibody in development to treat rheumatoid arthritis that it says it expects to market at an annual cost of just $2,000 a year. That compares to around $30,000 a year for drugs such as Humira, Remicade, and Enbrel that are TNF inhibitors. The experimental therapeutic known as Gerilimzumab targets IL-6. We spoke to Paul Grayson, president and CEO of Bird Rock Bio about the company, the benefits of targeting IL-6, and how the company expects to be able to offer the drug at such a disruptive price point.
The embattled pharma executive Martin Shkreli, whether intentional or not, has ignited a long smoldering public policy discussion about the pricing of pharmaceuticals. As there are growing calls for steps to restrain drug prices, there are also industry concerns about the effect such actions would have on the ability to attract investment and pursue the development of high-risk, innovative therapies. We spoke to Denis Corin, CEO of Q BioMed, an acceleration and development company, for a perspective on the fallout from Shkreli, how to balance innovation with affordability, and whether he expects any lasting impacts on small drug developers.
Peter Collins and Dr. Pepper Denman, both with Premaitha Health, spoke with Phillips Kuhl of CHI. The topics covered in the podcast include perspectives on the differences between the U.S. and European markets for cell-free DNA prenatal testing, including the pros and cons of conducting such testing in-house compared to sending samples out for testing by a service provider. Premaitha’s position regarding whether or not to extend testing to sub-chromosomal genetic aberrations, specifically micro-deletions, is also addressed. For more information, visit http://www.MolecularDXEurope.com/
CHI president Phillips Kuhl and Sequenom CMO Daniel Grosu discuss how Sequenom is applying new technology to address the next sets of clinical questions for non-invasive prenatal testing. To learn more, please visit http://www.MolecularDXEurope.com/
György Kosztolányi, Ph.D., President, Human Reproduction Committee of Scientific Health Council, Professor Emeritus, University of Pécs, Hungary spoke to CHI to discuss the ethical challenges of preimplantation testing as well the latest research and developments, including the potential for using extracellular DNA. He also raises questions on whether IVF babies, when they grow into adults, might view their genetic information and how we may handle this in the future. Dr. Kosztolányi is our moderator for the closing panel discussion at the Reproductive Genetic Diagnostics conference, taking place 6-7 April as part of the Molecular Diagnostics Europe event. For details, visit http://www.MolecularDXEurope.com/Reproductive-Genetic-DX/
Samantha A. Schrier Vergano of Children’s Hospital of the King’s Daughters speaks to Cambridge Healthtech Institute on February 15, 2016. Dr. Schrier Vergano will give her presentation during a shared session for the Clinical Genomics and Open Source Innovations conferences at Bio-IT World Conference & Expo, April 5-7 in Boston, Massachusetts. Topics include challenges when validating clinical utility of genetic variants, ethical quandaries of sharing genetic data in clinical settings and focusing on medical genetics with a pediatric angle. To learn more, please visit http://www.Bio-ITWorldExpo.com/
The California Institute for Regenerative Medicine, California’s voter-established stem cell agency, is thinking about its future. The institute recently issued a strategic plan for the next five years that it says represents a “radical overhaul of the way the institute conducts business” and emphasizes “coordination, speed, partnerships, and patients.” We spoke to Randy Mills, president of the California Institute for Regenerative Medicine, about the strategic plan, the ambitious goal it has set for the next five years, and whether CIRM will have a life beyond the $3 billion voters approved for its funding.
Kelly Ranallo, a rare patient advocate in Kansas City, is using World Rare Disease Day as a way to bring together the rare disease community in the region at a town hall meeting and to use that meeting to drive new initiatives. We spoke to Ranallo about her new organization Rare KC, the upcoming town hall meeting, and her vision for turning Kansas City into the home of a national center of excellence for rare diseases.
CHI recently interviewed Jonathan Hughes, Partner and Practice Lead of Outsourcing and Supply Chain Management at Vantage Partners about the evolution of Sponsor-CRO strategic partnerships to date; challenges and opportunities in forming these types of partnerships; and an outlook on how these partnerships will continue to evolve. Discussion points and questions include: 1. Can you tell us a bit about yourself and the role you play at Vantage? 2. Forming strategic alliances with CROs has not traditionally been the route sponsors have taken. Why has this changed and where are we now? Also, how have sponsors and CROs adapted over the years? 3. What are some of the unforeseen risks and benefits of moving beyond a traditional customer-vendor relationship? 4. During the upcoming Strategic Alliance Management Congress Vantage will be hosting a luncheon workshop focused on managing sponsor-CRO partnerships. Can you give us any insights as to what attendees can expect to learn during this? ...
Filmed live at ASM Biodefense 2016 with special guests: Rebekah Kading and Wyndham Lathem. From the ASM Biodefense and Emerging Diseases Research meeting, Vincent Racaniello speaks with Rebekah and Wyndham about their work on Rift Valley Fever virus and other vector-borne pathogens, and the evolution and pathogenesis of Yersinia pestis, the agent of plague. See the video version at microbeworld.org/mwv
By email@example.com (American Society for Microbiology)
Louis Fiore of Veterans Affairs Boston Healthcare System speaks to Cambridge Healthtech Institute on February 10, 2016. Dr. Fiore will give his presentation during a shared session for the Clinical Genomics and Cancer Informatics conferences at Bio-IT World Conference & Expo, April 5-7 in Boston, Massachusetts. Topics include aggregating and reusing Electronic Health Record (EHR) data for quality improvement, discovery and validation of genomic knowledge; MAVERIC's Point of Care Research Program and Precision Oncology Program; the value of Veterans Affairs programs for clinical genomics research; and empowering clinicians to make more informed decisions for patients. To find out more, visit http://www.Bio-ITWorldExpo.com/
About 1.3 million people in the United States have type 1 diabetes, which requires constant monitoring and regular injections of insulin. The autoimmune disease attacks the insulin producing beta cells in the pancreas and replacement of those cells has long been viewed as an ideal approach to treating the disease. The problem, though, has been finding a reliable supply or replacement cells and protecting them from the body’s immune system while allowing them to recieve needed nutrients, as well as deliver insulin to the body. San Diego-based ViaCyte is now in human clinical trials with a promising approach to treating the disease. We spoke to Paul Laikind, president and CEO of ViaCyte, about the company’s cell therapy, its critical financial support from the California Institute for Regenerative Medicine and JDRF, and why its investigational product may represent a functional cure.
Non-steroidal anti-inflammatory drugs are the most widely used medications in the world. They are used to treat pain resulting from diseases such as arthritis, but these drugs can raise blood pressure and cause serious problems including heart attacks, strokes, and death. We spoke to Paul Waymack, founder, chairman, and chief medical officer of Kitov Pharmaceuticals about its efforts to bring to market a combination therapy that addresses these safety concerns. Waymack discussed the issues surrounding pain medications, his company’s approach, and how the company’s smart FDA strategy is significantly cutting its cost and time to market.
Ralph Minter of MedImmune will describe his approach for phenotypic antibody screening and how it is being used to discover both novel antibodies and targets. He will discuss tips for overcoming obstacles to identifying novel targets, share advice for getting best results with phenotypic screening and describe how this work has been impacted by recent discoveries in the tumor microenvironment. For more information, please visit http://www.PEGSummit.com/
CHI recently interviewed Dr. Dmitry Samarsky, Senior Vice President of Technology and Global Business Development at OliX Pharmaceuticals, regarding the evolution of nucleic acid-based therapeutics; challenges within this space; recent advances in chemistry and delivery; and the greatest opportunities within this space over the next few years. Discussion questions include: 1 Given the obvious benefit of oligonucleotide therapies being able to dramatically expand target space, why haven’t they impacted the drug development landscape as much as Biologics or small Molecules? What challenges have been encountered within this field? 2 It seems as if there has be a resurgence of interest in the discovery and development of oligonucleotide therapeutics. Why do you think this is? What has changed over the past few years? 3 You are hosting a workshop during the upcoming Oligonucleotide Therapeutics and Delivery conference, providing an overview of oligonucleotide therapeutics from discovery ...
Romney Humphries, Assistant Professor, UCLA Pathology & Laboratory Medicine, Section Chief of Clinical Microbiology, David Geffen School of Medicine, University of California, Los Angeles spoke to CHI to discuss how Next-Generation Sequencing has changed the way scientists detect antimicrobial resistance as well as the challenges scienctists face moving forward. Dr. Humprhies is one of our speakers at the Molecular Diagnostics for Infectious Disease conference, taking place March 7-9 as part of the Molecular Medicine TriConference. For details, visit http://www.TriConference.com/Molecular-Diagnostics-for-Infectious-Disease/
Why are obesity, juvenile diabetes and asthma increasing? Is it something in the environment or in our modern lifestyle? Dr. Martin Blaser thinks that it may be due to changes in our microbiome – the ecosystem of tiny microscopic creatures that live in and on us. Learn about his hypothesis that some of the greatest medical advances in the 20th century – antibiotics, C-sections and antiseptics- may be having unintended consequences. Dr. Martin Blaser has studied the role of bacteria in human disease for over 30 years. He is the director of the Human Microbiome Program at NYU. He founded the Bellevue Literary Review and has been written about in newspapers including The New Yorker, Nature, Science, The New York Times, The Washington Post, and The Wall Street Journal. His more than 100 media appearances include The Today Show, The Daily Show, Fresh Air (NPR) GMA, the BBC, The O'Reilly Factor, and CNN. He lives in New York City.
By firstname.lastname@example.org (American Society for Microbiology)
The American Association for Cancer Research, with seven leading cancer research centers, has launched Project GENIE to determine how to better tailor treatments to patients’ individual cancers. The effort will take tumor genomic profiling data from the various institutions and aggregate it into a single database for researchers to harness. We spoke to Barrett Rollins, chief scientific officer at the Dana-Farber Cancer Institute, about the project, how far down the path of precision medicine we have travelled, and how he expects it to reshape cancer care in the years to come.
As medical device makers are building network connectivity and intelligence into their products, they are adding new vulnerabilities and risks as well. The U.S. Food and Drug Administration has just issued draft guidance for postmarket management of cybersecurity of medical devices. It follows previous guidance on premarket submissions for management of cybersecurity in medical devices. We spoke to Russell Jones, partner with Deloitte & Touche, cyber risk leader for the firm’s State of California Practice and co-leader of the firm’s medical device safety and security practice, about the FDA actions, how these connected devices can be exploited by hackers, and what medical device makers can learn from industries that have already faced these issues.
The pharmaceutical industry appears to have lost ground in 2015 on the ongoing debate around drug pricing, a problem that Christopher Bowe sees in part as a failure of leadership within the industry. In a recent guest column in Forbes, Bowe, who advises industry CEOs on communicating their strategies and ideas, argued that the industry needs CEOs capable of reframing the discussion with fresh ideas, forging new alliances, and disrupting existing business models. We spoke to Bowe about this leadership vacuum, why it is critical for the industry to move beyond its tired arguments, and what it needs to do to rebuild trust and credibility with the public.
CHI speaks with Dr. Klaus Pantel, a professor and founding director of the Institute of Tumor Biology at the University Medical Center Hamburg-Eppendorf in Germany. In this podcast Dr. Pantel discusses the steps needed to make liquid biopsy the standard-of-care, its most promising applications, and future directions. Dr. Pantel also adds his voice to the debate over whether or not early detection is viable, and in which indications it may make the most sense. For more information, please visit http://www.MolecularDXEurope.com/
CHI chats with Dr. Raymond J. Langley, Assistant Professor, Department of Pharmacology, University of South Alabama. Dr. Langley discusses the latest research and developments in metabolomics risk analysis models for sepsis and predictive biomarkers for patient survival, as well as the current challenges in developing technology for metabolomics diagnostics for sepsis. Dr. Langley is one of our speakers at the Molecular Diagnostics for Infectious Disease conference, taking place March 7-9 as part of the . For details, visit http://www.TriConference.com/Molecular-Diagnostics-for-Infectious-Disease/
As 2015 came to a close, Congress passed a package of tax extenders that among other things expanded the Research and Development Tax Credit and made it permanent. The move represents a big win for innovation-based industries, but the life sciences in particular, which will benefit from a new provision that allows companies to capitalize on the credit ahead of producing revenue. We spoke to Dan Mennel, California Market Leader of Strategic Federal Tax Services for Grant Thorton and Matt Gardner, CEO of the California Technology Council, about the R&D tax credit, what it does, and what it means for the life sciences.
The year 2015 was another big one for biotech with record dealmaking, big drug approvals, and solid performance, but it somehow didn’t feel as good as it looks on paper. Pricing concerns that garnered big attention are expected to grow in intensity in the new year with the presidential election and negotiations for the renewal of the Prescription Drug User Fee Act. We spoke to Adam Feuerstein, senior columnist for TheStreet.com, about the year in biotech, the highs and lows, and what’s ahead in the new year.
CHI chats with Bert Smeets, Ph.D., Professor, Clinical Genomics, Mitochondrial Diseases, Maastricht University Medical Center. Dr. Smeets discusses the latest research and developments on diagnosing mtDNA disease using Next-Generation Sequencing, as well as his work in developing techniques to prevent mtDNA disease transmission and developing therapeutics for those affected by mtDNA disease. Dr. Smeets is one of our speakers for the Novel Diagnostic Approaches session at the Reproductive Genetic Diagnostics conference, 6-7 April, in Lisbon. For details, visit http://www.MolecularDXEurope.com/Reproductive-Genetic-DX
Growing costs pressures, the integration of technology, and the transformation of the patient into a healthcare consumer is giving rise to a new health economy. In its report on the top health industry issue for 2016, PwC highlights the forces expected to have the most impact on the industry in the coming year. We spoke to Karla Anderson, principal of U.S. pharmaceuticals and life sciences for PwC, about the report, how an increasing emphasis on value is reshaping the sector, and what’s in store for 2016.
Nature Biotechnology talked to Wilson about his love of motocross racing, the triumphs and tribulation of gene therapy (including the Jesse Gelsinger tragedy), and the future of drug pricing.
By email@example.com (Nature Biotechnology)
Despite a record number of new drug approvals this year, the return on R&D investment for the largest pharmaceutical companies continues to fall, according to a new report from the Deloitte Centre for Health Solutions and Deloitte’s R&D services group. In fact, the report finds R&D returns for this group of companies have fallen to their lowest point since Deloitte began tracking them in 2010. We spoke to Neil Lesser, principal with Deloitte Consulting in the Life Sciences strategy practice and a leader in the Research & Development strategy practice, about the report, the pressures on the industry that are hurting returns, and what R&D strategies companies can pursue that might reverse the trend.
Peter Luppa of the Technishe Universität in München will outline what he considers some of the greatest obstacles to implementing POC testing in the clinical setting and describe the need for quality standards. He will share advice for introducing POCT within the clinical setting and some of the most exciting applications emerging for POC and how they fit into the theranostic/health monitoring ecosystem.